Skip to main content

Advertisement

SpringerLink
Log in

Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the efficacy of brolucizumab, half-dose PDT, and aflibercept in treating chronic central serous chorioretinopathy (CSC).

Methods

A retrospective cohort study with chronic CSC patients who underwent intravitreal injection of one shot of brolucizumab or aflibercept in the first 3 months, followed by pro re nata regimens or a single session of half-dose PDT, was retrospectively reviewed. The primary outcome measure was the proportion of eyes that achieved complete absorption of retinal fluid without requiring any rescue treatment. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and central choroidal thickness (CCT).

Results

A total of 54 consecutive patients were included in this study with 18 patients in each group. At months 1 and 2, the brolucizumab group exhibited the highest rate of complete retinal fluid resolution (61% and 77%), followed by the half-dose PDT group (56% and 72%), and lowest in the aflibercept group (28% and 33%), with statistically significant differences noted at month 2 (P = 0.012). The brolucizumab group also demonstrated the most significant reduction in CCT at months 1 and 2 among the three groups (P = 0.007 and 0.001). Recurrence of retinal fluid in the brolucizumab groups was predominantly observed at month 3. Conversely, the half-dose PDT group exhibited the most favorable anatomical results starting from month 3. Notably, mild vitritis was observed in one case from the brolucizumab group.

Conclusions

Single injection of brolucizumab demonstrates trends of faster regression of persistent residual retinal fluid, greater CCT and CRT decline, and matched BCVA compared to half-dose PDT in the short term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. van Rijssen TJ, van Dijk EHC, Yzer S et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https://doi.org/10.1016/j.preteyeres.2019.07.003

    Article  PubMed  Google Scholar 

  2. Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63(Suppl):1–139

    Google Scholar 

  3. Marmor MF (1988) New hypotheses on the pathogenesis and treatment of serous retinal detachment. Graefes Arch Clin Exp Ophthalmol 1226:548–552. https://doi.org/10.1007/BF02169203

    Article  Google Scholar 

  4. Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB (2019) Pachychoroid disease. Eye (Lond) 33:14–33. https://doi.org/10.1038/s41433-018-0158-4

    Article  PubMed  Google Scholar 

  5. Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina 37:1905–1915. https://doi.org/10.1097/IAE.0000000000001443

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chen SN, Hwang JF, Tseng LF, Lin CJ (2008) Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 115:2229–2234. https://doi.org/10.1016/j.ophtha.2008.08.026

    Article  PubMed  Google Scholar 

  7. You EL, Hébert M, Jin TS, Bourgault S, Caissie M, Tourville É, Chen J, Ordóñez-Mena J, Dirani A (2023) Comparing interventions for chronic central serous chorioretinopathy: a network meta-analysis. Surv Ophthalmol 68:601–614. https://doi.org/10.1016/j.survophthal.2023.03.001

    Article  PubMed  Google Scholar 

  8. van Dijk EHC, Feenstra HMA, Bjerager J, Grauslund J, Boon CJF, Subhi Y (2023) Comparative efficacy of treatments for chronic central serous chorioretinopathy: a systematic review with network meta-analyses. Acta Ophthalmol 101:140–159. https://doi.org/10.1111/aos.15263

    Article  PubMed  CAS  Google Scholar 

  9. Tseng CC, Chen SN (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99:1070–1077. https://doi.org/10.1136/bjophthalmol-2014-305353

    Article  PubMed  Google Scholar 

  10. Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, Tsang CW, Brelén ME (2016) A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 170:91–99. https://doi.org/10.1016/j.ajo.2016.07.026

    Article  PubMed  Google Scholar 

  11. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H (2010) Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 35:91–98. https://doi.org/10.3109/02713680903428306

    Article  PubMed  CAS  Google Scholar 

  12. Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C (2012) Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol 56:608–612. https://doi.org/10.1007/s10384-012-0162-3

    Article  PubMed  CAS  Google Scholar 

  13. Khanani AM, Brown DM, Jaffe GJ, Wykoff CC, Adiguzel E, Wong R, Meng X, Heier JS, Investigators MERLIN (2022) MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology 129:974–985. https://doi.org/10.1016/j.ophtha.2022.04.028

    Article  PubMed  Google Scholar 

  14. Mukai R, Matsumoto H, Nagai K, Akiyama H (2022) Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment. BMC Ophthalmol 22:387. https://doi.org/10.1186/s12886-022-02617-2

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128:89–99. https://doi.org/10.1016/j.ophtha.2020.06.028

    Article  PubMed  Google Scholar 

  16. Brown DM, Emanuelli A, Bandello F et al (2022) KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol 238:157–172. https://doi.org/10.1016/j.ajo.2022.01.004

    Article  PubMed  CAS  Google Scholar 

  17. Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, Wieland M, Singerman L (2017) Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology 124:1296–1304. https://doi.org/10.1016/j.ophtha.2017.03.057

    Article  PubMed  Google Scholar 

  18. Liegl RG, Karcher H, Chetty-Mhlanga S, Igwe F, Freitas R (2023) The treatment patterns with brolucizumab in Germany (REALIZE) study: a retrospective cohort study based on longitudinal prescription data. Ophthalmol Ther 12:195–208. https://doi.org/10.1007/s40123-022-00596-7

    Article  PubMed  Google Scholar 

  19. Torres-Soriano ME, García-Aguirre G, Kon-Jara V, Ustariz-Gonzáles O, Abraham-Marín M, Ober MD, Quiroz-Mercado H (2008) A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 246:1235–1239. https://doi.org/10.1007/s00417-008-0856-x

    Article  PubMed  CAS  Google Scholar 

  20. Lim JW, Kim MU, Shin MC (2010) Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 30:1465–1471. https://doi.org/10.1097/IAE.0b013e3181d8e7fe

    Article  PubMed  Google Scholar 

  21. Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC (2015) A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol 99:848–852. https://doi.org/10.1136/bjophthalmol-2014-306018

    Article  PubMed  Google Scholar 

  22. Fukuda Y, Sakurada Y, Matsubara M, Hasebe Y, Sugiyama A, Kikushima W, Kashiwagi K (2021) Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines 9:1164. https://doi.org/10.3390/biomedicines9091164

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Kitajima Y, Maruyama-Inoue M, Ikeda S, Ito A, Inoue T, Yanagi Y, Kadonosono K (2022) Short-term outcomes of switching to brolucizumab in Japanese patients with neovascular age-related macular degeneration. Jpn J Ophthalmol 66:511–517. https://doi.org/10.1007/s10384-022-00940-1

    Article  PubMed  CAS  Google Scholar 

  24. van Dijk EHC, Fauser S, Breukink MB et al (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 125:1547–1555. https://doi.org/10.1016/j.ophtha.2018.04.021

    Article  PubMed  Google Scholar 

  25. Ratanasukon M, Thongthong K, Bhurayanontachai P, Jirarattanasopa P (2013) Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy. Clin Ophthalmol 7:87–92. https://doi.org/10.2147/OPTH.S39584

    Article  PubMed  PubMed Central  Google Scholar 

  26. Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, Park TK, Moon SW, Chung H (2011) A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 152:784–92.e2. https://doi.org/10.1016/j.ajo.2011.04.008

    Article  PubMed  CAS  Google Scholar 

  27. Sirks MJ, van Dijk EHC, Rosenberg N et al (2022) Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. Acta Ophthalmol 100:e1522–e1532. https://doi.org/10.1111/aos.15148

    Article  PubMed  PubMed Central  Google Scholar 

  28. Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A (2013) Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond) 27:612–620. https://doi.org/10.1038/eye.2013.24

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Eye Center, China Medical University Hospital, 2 Yuh-Der Road, Taichung City, 40447, Taiwan

    Yu-Te Huang, Peng-Tai Tien, Po-Yu Chen, Chi-Lan Yang & San-Ni Chen

  2. School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

    Peng-Tai Tien & San-Ni Chen

Authors
  1. Yu-Te Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peng-Tai Tien
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Po-Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chi-Lan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. San-Ni Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to San-Ni Chen.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the China Medical University Hospital Research Ethics Committee (CMUH111-REC1-192) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Owing to the retrospective design of the study and the use of deidentified patient information, the review board waived the need for written informed consent.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, YT., Tien, PT., Chen, PY. et al. Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol (2024). https://doi.org/10.1007/s00417-024-06373-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00417-024-06373-5

Keywords

Search

Navigation